Dr Min Yeo

17/06/2026

Type 1 diabetes was once thought to be exclusively a childhood-onset disease, but recent evidence shows that more than half of all diagnoses of type 1 diabetes occur in adulthood.

A recent research letter aims to address the current gaps in knowledge, and discusses systematic screening for early-stage type 1 diabetes after childhood ▶️ http://spkl.io/61837DYwc

👇 Figure: Islet autoantibody assessment.

12/06/2026

The results of a study in Nature Metabolism establish hyperglycosylation as a pathological driver of Alzheimer’s disease and highlight glycan metabolism as an actionable target in the fight against the disease.

Link to the research in the comments.

12/06/2026

Current evidence supports the use of this botanical agent to promote skin health, but more research is needed to ascertain more varied and curative applications for this popular natural product.

01/06/2026

In a 2025 Review, researchers discussed how interactions between the nervous and immune systems could impact neurological disorders and allergy-related behaviors like food avoidance.

Learn more: https://scim.ag/3FcZ5Ki

29/05/2026

29/05/2026

In a new blog post, Dr. Michelle Kittleson writes that clinical decisions should be driven by the patient’s medical needs, not by physician concerns about their status, expectations, or perceptions.

28/05/2026

A high intake of widely used preservative food additives is associated with increased risks of developing hypertension and cardiovascular disease.

14/05/2026

Polycystic o***y syndrome (PCOS) is estimated to affect over 170 million women worldwide during their reproductive years alone.

Recently, experts have agreed on a new name, Polyendocrine Metabolic Ovarian Syndrome (PMOS), to reflects the condition’s wide-ranging endocrine and metabolic features, and to help reduce misunderstandings about the disease. Find out more ▶️ http://spkl.io/6189ACRxB

👇 Panel: Context and the case for a new name.

13/05/2026

About 20 years ago, neuropathologists began to report an inconvenient finding in the autopsied brains of people with dementia: Most have evidence of more than one disease. Studies since have shown the brains of up to half of people diagnosed with Alzheimer’s disease also have a key feature of Parkinson’s disease—deposits of the protein alpha synuclein. At the same time, up to half of Parkinson’s patients who develop dementia have elevated levels of beta amyloid and tau proteins, hallmarks of Alzheimer’s.

Researchers studying neurodegenerative diseases are catching on to the importance of this phenomenon, often called copathology.

Tests now being developed to pick up multiple biomarkers should give a clearer picture of these mixed pathologies in living patients. And an upcoming clinical trial will be the first to take aim at a common dementia copathology, testing the amyloid-clearing Alzheimer’s drug donanemab in people who have both amyloid in their brains and dementia with Lewy bodies—abnormal clumps of alpha synuclein.

Learn more: https://scim.ag/4ujMAkn